Emerging therapies for glioblastoma: current state and future directions

L Rong, N Li, Z Zhang - Journal of Experimental & Clinical Cancer …, 2022 - Springer
Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …

[HTML][HTML] Immunotherapy for glioma: current management and future application

S Xu, L Tang, X Li, F Fan, Z Liu - Cancer letters, 2020 - Elsevier
Gliomas are intrinsic brain tumors that originate from neuroglial progenitor cells.
Conventional therapies, including surgery, chemotherapy, and radiotherapy, have achieved …

Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial

DA Reardon, AA Brandes, A Omuro… - JAMA …, 2020 - jamanetwork.com
Importance Clinical outcomes for glioblastoma remain poor. Treatment with immune
checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from …

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

TF Cloughesy, AY Mochizuki, JR Orpilla, W Hugo… - Nature medicine, 2019 - nature.com
Glioblastoma is the most common primary malignant brain tumor in adults and is associated
with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a …

Mechanisms of immunotherapy resistance: lessons from glioblastoma

CM Jackson, J Choi, M Lim - Nature immunology, 2019 - nature.com
Glioblastoma (GBM) is the deadliest form of brain cancer, with a median survival of less than
2 years despite surgical resection, radiation, and chemotherapy. GBM's rapid progression …

Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis

Y Wang, S Zhou, F Yang, X Qi, X Wang, X Guan… - JAMA …, 2019 - jamanetwork.com
Importance Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1)
inhibitors have been increasingly used in cancer therapy. Understanding the treatment …

Current state of immunotherapy for glioblastoma

M Lim, Y Xia, C Bettegowda, M Weller - Nature reviews Clinical …, 2018 - nature.com
Glioma is the most common primary cancer of the central nervous system, and around 50%
of patients present with the most aggressive form of the disease, glioblastoma. Conventional …

A H3K27M-targeted vaccine in adults with diffuse midline glioma

N Grassl, I Poschke, K Lindner, L Bunse… - Nature Medicine, 2023 - nature.com
Substitution of lysine 27 to methionine in histone H3 (H3K27M) defines an aggressive
subtype of diffuse glioma. Previous studies have shown that a H3K27M-specific long peptide …

Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors

P Chongsathidkiet, C Jackson, S Koyama, F Loebel… - Nature medicine, 2018 - nature.com
T cell dysfunction contributes to tumor immune escape in patients with cancer and is
particularly severe amidst glioblastoma (GBM). Among other defects, T cell lymphopenia is …

Multidimensional communication in the microenvirons of glioblastoma

ML Broekman, SLN Maas, ER Abels… - Nature Reviews …, 2018 - nature.com
Glioblastomas are heterogeneous and invariably lethal tumours. They are characterized by
genetic and epigenetic variations among tumour cells, which makes the development of …